Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
W. Jonat1*, T. Bachelot2, T. Ruhstaller3, I. Kuss4, U. Reimann4 & J. F. R. Robertson5 Department of Gynaecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Medical Oncology and Lyon Cancer Research Centre, Centre Léon Bérard, Lyon, France; Breast Centre St. Gallen, Kantonsspital St. Gallen, St. Gallen, Switzerland; Bayer Pharma AG, Berlin, Germany; Academic Division of Breast Surgery, University of Nottingham, Royal Derby Hospital, Derby, UK